cyrilzakka/clinical-trials huggingface dataset:
Effects Of Neurocognitive Therapy With And Without Soft Robotic Hand On Hand Function

To determine the effect of neurocognitive therapy with and without a soft robotic hand on manual ability, dexterity, strength, spasticity and upper limb function in sub-acute stroke.

Stroke is a global disease with high death rate and high disability caused by motor cortical damage. According to the calculations, there were approximately 13.68 million new increased stroke patients all over the world a year and about 70% of survivors had diﬀerent degrees of upper limb and hand movement dysfunction .The recovery rate of patients' motor function mainly depends on rehabilitation training. Therefore, due to individual diﬀerence of patients. Neurocognitive therapy is an effective therapy to improve and increase cognitive, sensory and motor function of upper limb. Robotic hand also help the function of weak hand muscle. Neurocognitive therapy with a robotic hand will have the potential to offer targeted, precise, and adaptable interventions, possibly increase the rehabilitation process compared to both interventions alone. Evaluating their relative efficacy will aid in refining and tailoring rehabilitation strategies for individuals recovering from acute stroke.

Eligibility Criteria:
Inclusion Criteria:

* Participants of Post stroke patients (6-12 weeks )
* Participants with Spasticity \< 2 on modified Ashworth scale.
* Participants with first ever stroke.
* Participants with normal cognition \> 24 on MoCA
* Participants must be able to provide informed consent
* Hemiparesis with arm motor deficit as assessed by with NIHSS \>1(14)

Exclusion Criteria:

* Participants who have a history of significant neurological or orthopedic disorders, other than stroke, that could interfere with upper limb motor or sensory recovery.
* Participants who have altered state of consciousness, severe aphasia, severe cognitive deficit.
* Participants who have severe pathologies of traumatic and or rheumatic nature, severe pain in effected arm (\>5 on visual analog scale for pain) .
* Participants who have active pacemakers and other active implants.
Do Hostility and Stress Predict Cardiovascular Mortality in MRFIT?

To test the hypothesis that high levels of hostility, depressive symptoms, and stressful life events would be associated with all cause and cardiovascular disease (CVD) mortality after 16 years of follow-up in the Multiple Risk Factor Intervention Trial (MRFIT).

BACKGROUND:

MRFIT was a randomized, multicenter primary prevention trial designed to determine whether a special intervention consisting of smoking cessation, cholesterol reduction and control of high blood pressure, would result in a significant reduction in coronary heart disease (CHD) mortality, compared to usual care. The study presented a unique opportunity to test in a cost-efficient manner the association of psychosocial factors and mortality in a large, well characterized sample of middle-aged men.

DESIGN NARRATIVE:

The sample was composed of 12,866 men who at the time of study entry were in the top 15 percent of a risk score distribution based on the Framingham Heart Study data, but had no clinical evidence of CHD. During the trial, annual measurements were taken, which included some health behaviors, stressful life events, feelings of anger and hostility. A subset of 3,110 men also were administered once the Type A Structured Interview from which Potential for Hostility could be rated and all men who survived until the sixth year of the trial were administered the CES-Depression scale.

After approximately seven years of the active phase of the trial, the men were followed for an additional 9 years for mortality and cause of death. To test the major study hypotheses, the investigators coded all Type A Structured Interview tapes for Potential for Hostility, and components of hostility (Style, Intensity, Content) and constructed and validated a self-report measure of hostility from items administered to all participants. Cox proportional hazard regression techniques were used to test the association of hostility, depression, and stressful life events with all cause and CVD mortality. If the major study hypotheses were confirmed, then educational attainment, baseline risk factors, change in risk factors, and adherence indicators would be included in subsequent analyses.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

Eligibility Criteria:
No eligibility criteria
Monitored Anesthesia Care With Propofol Plus Remifentanil During Endoscopic Submucosal Dissection: Evaluation of Bispectral Index Monitoring

There are clinical usefulness issues associated with bispectral index (BIS) for sedation of endoscopic submucosal dissection (ESD). However, the clinical usefulness of BIS for deep sedation is incompletely described. The purpose of this study is to show that BIS-guided sedation is safe and useful clinically and may provide stable sedation status to physicians and patients.


Eligibility Criteria:
Inclusion Criteria:

* American Society of Anesthesiologists (ASA) physical status I to II.

Exclusion Criteria:

* body mass index (BMI) over 35 (Kg/m2)
* hepatic or renal insufficiency
* history of allergy to the drugs used
* history of administration of anxiolytics, narcotics, antipsychotics, opioid.
HPV and Male Homosexuality in General Practice?

The main objective of this study is to find out whether young MSM (men who have sex with men) believe it is important for their GP to be informed of their sexual orientation, in order to improve their clinical, especially with HPV vaccination.

The secondary objective is to analyze the state of knowledge about the HPV vaccine and the value of HPV vaccine in this target population.


Eligibility Criteria:
Inclusion criteria:

* Age: 18-26 years
* Consultation at the HUS Cegidd as part of an STI screening
* Subject who expressed no opposition to participating in the study

Exclusion criteria:

* Refusal of the patient to participate in the study
* Subject who had already benefited from HPV vaccination (at least one dose)
* Inability to give informed consent
* Subject under safeguarde of justice
* Subject under guardianship or under curatorship
The Effect of Propofol or Sevoflurane on Renal Function

This study investigates the role of the anesthetic agents propofol and sevoflurane on renal function in otherwise healthy patients undergoing basic back surgery.

Water-sodium homeostasis is central for anyone undergoing surgery, and can therefore affect surgical outcome, level of postoperative care and the length of hospital stay. Too much or too little fluid during surgery can affect the patients negatively. The kidneys play an imperative role in the regulation of water and sodium homeostasis, however there are lack of knowledge in how the anesthesia per se affects renal function. Previous studies have shown that volatile anesthetic agents such as sevoflurane can cause fluid retention. Why this happens is not completely known.

We are now investigating the different affects of sevoflurane and propofol anesthesia on renal function in patients undergoing basic back surgery to elucidate if there is a difference in the risk of developing acute kidney injury.

Eligibility Criteria:
Inclusion Criteria:

* Scheduled back surgery

Exclusion Criteria:

* American Association of Anesthesiology class 1-3
* American Heart Association class \>3
* BMI \>37
* Insulin treated diabetes
* Pregnancy or breast feeding
* Sensistivity/allergy against anesthetic agents
* Inadequate understanding about the study
* Depressed kidney function and/or AKI
* Depressed liver function
* Genetic malignant hyperthermia
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer.


Eligibility Criteria:
Inclusion Criteria:

* Written informed consent
* Histologically confirmed adenocarcinoma of prostate
* Ongoing androgen deprivation therapy with a LHRH analogue or antagonist or bilateral orchiectomy
* Progressive metastatic disease
* Adequate bone marrow, hepatic, and renal function

Exclusion Criteria:

* Known metastases in the brain
* History of other malignancy within the previous 5 years
* Known gastrointestinal disease or procedure that affects the absorption
* Not able to swallow the study drug
Postpartum Etonogestrel Implant for Adolescents

This is a prospective study comparing two groups of 48 adolescent women each. The intervention group will receive a contraceptive implant postpartum, prior to discharge from the hospital. The control group will receive a contraceptive implant at the usual 6 week postpartum clinic visit. During prenatal care, participants will be consented and screened for enrollment. After delivery, these women will be assessed and consented for enrollment into the study. Women who consent for enrollment will be randomized. Women will be followed up at 3 months, 6 months, 9 months, and 1 year after contraceptive implant insertion. At each follow up, women will be assessed for continuation of and satisfaction with this method of contraception.


Eligibility Criteria:
Inclusion Criteria:

* Adolescents ages 14-24 attending prenatal care
* Greater than 20 weeks estimated gestational age
* English or Spanish-speaking
* Desire to use the contraceptive implant for contraception postpartum
* Anticipated delivery of a healthy infant vaginally or by cesarean.

Exclusion Criteria:

Participants will not be eligible for participation if they have any contraindications to contraceptive implant use, including

* current or past history of thrombosis or thromboembolic disorders
* hepatic tumors (benign or malignant)
* active liver disease
* undiagnosed abnormal genital bleeding
* known or suspected carcinoma of the breast (or a personal history of breast cancer)
* hypersensitivity to any of the components of the contraceptive implant.
* Current use of any medications known to induce hepatic enzymes, including but not limited to: barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John's wort, or topiramate

Characteristics that would preclude involvement after delivery:

* Birth of a stillborn infant.
* Maternal ICU admission after delivery
* Maternal postpartum hemorrhage requiring blood transfusion
* Prolonged hospital stay (\>7 days) postpartum
* Coagulopathy associated with the pregnancy
* Severe pregnancy-induced hypertension
* Fever \>38 degrees C postpartum
* Adolescent women who are not competent to consent, secondary to stress from the labor process, for example severe pain or sleep deprivation, will not be offered enrolment into the trial
Psychological Problems in Post Thyroidectomy Patients

Quality of life (QoL) refers to perceived well-being, and encompasses the evaluation of physical health, and physical, social, and psychological functioning .

The assessment of quality of life (QOL) post-thyroidectomy has gained significant attention in the medical community. Multiple studies have delved into the long-term consequences of thyroidectomy, aiming to evaluate the impact on patients' overall well-being and functional status. By examining numerous aspects, such as the physical, psychological, and social dimensions of QOL, researchers have provided valuable insights into the outcomes of thyroidectomy, hence contributing to improving patient care and enhancing their postoperative experiences.

Regarding the psychological dimension of QOL, several studies have emphasized patients' emotional well-being post-thyroidectomy. Findings have demonstrated that, while many individuals experience temporary emotional disturbances related to the surgery, long-term psychological outcomes generally improve over time. In fact, the majority of patients report higher levels of self-esteem and body image post-thyroidectomy, as the removal of a diseased or abnormal thyroid gland can alleviate anxiety and distress associated with the underlying condition. However, additional research is needed to explore the specific factors contributing to these positive psychological outcomes and to identify potential interventions for those experiencing psychological distress following thyroidectomy .

Thyroidectomy is the treatment of choice in thyroid cancer patients, and the prevalence of thyroid cancer has shown a gradual increase over the past two decades. Thyroid surgery is also indicated in certain forms of benign thyroid disorder, such as nontoxic goiter and Graves' disease. Although thyroidectomy is a universal operation, few studies to date have investigated the impact of thyroidectomy on QOL .

Eligibility Criteria:
Inclusion Criteria:

* 1-Gender: both males and females 2- Post thyroidectomy patients: patients who will be planned to undergo different types of thyroidectomy for conditions such as thyroid cancer, benign thyroid disease (goiter), or hyperthyroidism (e.g., Graves' disease) and admitted as inpatients.

  3- Age Range: participants within certain age range (e.g., 18-75 years). 4-Consent: Ability to provide informed consent to participate in the study. 5-Stable Medical Condition:

Exclusion Criteria:

1. Patients who were previously diagnosed with any psychiatric diseases.
2. Medications: Use of medications that could affect outcome of the study e.g., antidepressants, corticosteroids and benzodiazepines
3. Pregnancy: Current pregnancy or breastfeeding.
4. Age: less than 18 years or more than 75 years old.
5. patients with any organ failure e.g (heart failure, end-stage renal disease requiring dialysis and liver failure) and cancers other than thyroid cancer.
REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction

The purpose of this study is to evaluate whether erythropoietin can help limit the damage to the heart in patients with acute heart attacks.

REVEAL is a randomized, double-blinded, placebo-controlled, parallel phase II clinical study that will evaluate the effects of erythropoietin administration on infarct size, left ventricular remodeling and circulating endothelial progenitor cells in patients with large myocardial infarctions (MI). The study will be conducted in two phases: a dose-escalation safety phase and a single dose efficacy phase. Eligible patients who present to the hospital with an acute ST-elevation MI and who agree to participate in this study will be randomly assigned to receive a single infusion of study medication consisting either of erythropoietin or placebo. The size of the infarction and the dimensions of the heart will be assessed by cardiac magnetic resonance imaging (MRI) within 2-6 days of the infusion of the study medication, and again approximately 3 months later.

Eligibility Criteria:
* INCLUSION CRITERIA:

Age greater than 21 years

Acute ST-elevation myocardial infarction

Referral for primary or rescue angioplasty

Revascularization procedure within 8 hours from the onset of ischemic symptoms

TIMI (Thrombolysis in myocardial infarction) flow grade 0 or 1 in the culprit coronary artery at the beginning of coronary angiography

Successful revascularization of infarct-related artery

EXCLUSION CRITERIA:

Clinical indication for erythropoietin

STEMI (ST-elevation myocardial infarction) due to occlusion of a branch vessel

Any history of prior MI, PCI (Percutaneous coronary intervention), CABG (Coronary artery bypass graft), cardiomyopathy, myocarditis, or CHF (congestive heart failure)

Hypersensitivity to human albumin, mammalian cell-derived products, or erythropoietin

Hematocrit greater than 42% in men or greater than 40% in women at the time of study drug administration

Uncontrolled hypertension at the time of study drug administration

Cardiogenic shock

Need for coronary surgical revascularization as determined at the time of the index coronary catheterization

History of hypercoagulable disorder, thromboembolic event, or venous thrombosis

History of stroke or TIA (transient ischemic attack)

History of seizures

Contraindication to MRI

Pregnancy or nursing mother
Does Mindfulness Training Change the Processing of Social Threat?

Training in mindfulness, the non-judgmental observation of experiences as they arise in the present moment, has been increasingly and successfully applied to the treatment of normative stress conditions and mental disorders. Yet, the neurological mechanisms that underlie the reported improvements are still largely unknown. This longitudinal study will investigate the influence of mindfulness training on a key underpinning of mental health, namely emotion regulation, and its associated brain activity. Healthy participants will be randomly assigned to either a validated eight week Mindfulness-based stress reduction (MBSR) program or to a control condition. In a pre-post investigation, participants' subjective reactions to aversive emotional stimuli (affective facial expressions) will be assessed, as will the associated brain activation using functional magnetic resonance imaging (fMRI). The investigators hypothesize that after the training the MBSR participants will rate the pictures as less aversive compared to control participants. Furthermore, the MBSR participants will show a patter of brain activation indicative of improved emotion regulation, relative to control participants. Finally, the effect of MBSR on the gray matter structure of the brain will be investigated.


Eligibility Criteria:
Inclusion Criteria:

* no previous significant meditation or yoga experience
* eligible for MRI scanning (no metallic implants, not pregnant, not claustrophobic)
* no significant previous meditation or yoga experience

Exclusion Criteria:

* DSM-IV diagnosis for depression, manic episodes, GAD, social phobia, anorexia, bulimia, schizophrenia, ADHD, substance dependency/abuse, suicidality
* ineligible for MRI scanning (metallic implants, pregnant, claustrophobic)
Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards

The goal of this observational study is to compare the recommendations of the artificial intelligence clinical decision support system 'ADBoard', with the recommendations of physicians by tumor conferences in patients with hepatobiliary tumors. The main questions it aims to answer are:

Can ADBoard achieve a high level of similar recommendations as physicians' tumor conferences? Can ADBoard consider a more complete set of patient-related data than in physicians' tumor conferences? Can ADBoard reduce the time between the first time the patient is discussed at the tumor conference and the start of the recommended treatment plan? Participants will have their hepatobiliary tumor treatments determined by either tumor conference with ADBoard, or tumor conference without ADBoard.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years
* Valid informed consent
* Patient information available in the hospital information system or Health Data Platform (HDP)
* Enrollment in the hepatobiliary tumor conference
* Diagnosis of any of the following entities: Colorectal liver metastasis, Gallbladder carcinoma, Hepatocellular carcinoma (HCC), mixed cell carcinoma, or fibrolamellar carcinoma, Perihilar cholangiocarcinoma (Klatskin tumors), Intrahepatic cholangiocarcinoma (iCC)

Exclusion Criteria:

* Patient does not consent / incapable of giving consent
* Missing findings in the hospital information system
* Patient is seeking for a second opinion and is not being treated at the study institution
Effect of Phytochemicals From Theobroma Cacao on Mental Energy

The purpose of this study is to determine which substances in cocoa produces changes in mental energy. This is a double blind study. The primary outcome measures are performance on tasks of sustained attention (serial subtract, continuous performance test and Bakan task) at pre and 90, 120 and 160 minutes post intervention, energy and fatigue symptoms (profile of mood state), and ratings of motivation to perform cognitive tasks. The assigned interventions are the following:

Only one prior study has examined the acute influence of cocoa on mental energy. The purpose of this research is to replicate the previous observations and extend research in four ways: 1) start to determine which substance in cocoa responsible for the effect by including several comparison groups, 2) focus on individuals with average or below average symptoms of mental energy and who are not high consumers of fruits, vegetables and other products containing high amounts of flavonoids in order to learn whether people with low energy accrue a greater benefit, and 3) include additional measures of mental energy plausibly influenced by cocoa to better understand the health consequences of cocoa.

Eligibility Criteria:
Inclusion Criteria:

* Women and men ages 18-34
* Lower than average feelings of energy (score of \< 13 on Profile of Mood States Vigor scale)

Exclusion Criteria:

* Pregnant
* GI tract disorder
* Psychoactive medication use
* Daily consumption of \> 200 mg caffeine
* Body mass index \> 30
* Cigarette smoker
* Allergy to cocoa, chocolate or caffeine
* Frequent consumption of cocoa, chocolate-based products or fruits and vegetable containing flavonoids
STD Testing in Outpatient Practices

National guidelines have recommended routine STD screening (chlamydia and gonorrhea) for sexually active young women under the age of 25. Despite these recommendations, many young women are not being screened for STDs, with some estimates that less than 50% of women receiving health care are screened for chlamydia. Untreated STDs can lead to important sequelae to women's reproductive health including pelvic inflammatory disease, infertility and ectopic pregnancy. One of the most important barriers to widespread STD screening is provider failure to recognize an opportunity for STD screening. The goal of this study is to determine whether offering STD screening (chlamydia and gonorrhea) by a non-physician member of the medical practice (who receives an automated alert indicating STD screening should be offered) will be associated with a higher rate of STD screening in young women attending primary care practices compared to usual care (where a physician offers screening with no electronic alert). This study will be performed in UPMC-affiliated primary care practices (Family Practice, Internal Medicine, OB/GYN, Pediatrics). Practices will be assigned to the intervention or usual care. The intervention will be an auto-task in the electronic medical record to the non-physician/NP/PA medical staff (medical assistants, LPNs, RNs) to offer chlamydia and gonorrhea screening via urine or self-collected vaginal sampling, in an opt-out manner, to eligible women. Practices assigned to the usual care group will not have the intervention. STD screening rates (# women undergoing STD screening/# eligible women) will be compared between the to groups (intervention practices and control practices). Results of this study may be important to guide national STD screening recommendations and will address critical barriers to widespread STD screening.


Eligibility Criteria:
Inclusion Criteria:

Women ages 15-24 Sexually Active Receiving care in one of the primary care offices affiliated with UPMC selected for this study.

Exclusion Criteria:

Pregnancy